Federal Register / Vol. 63, No. 18 /Wednesday, January 28, 1998 / Notices 4269

6. Part F.II(a)., Section 2692(a) of the

PHS Act—AIDS Education and Training

Centers (AETC);

7. Part F.II.(b)., Section 2692(b) of the

PHS Act—Dental Schools

Reimbursement Program.

This delegation supersedes the

delegation memorandum from the

Assistant Secretary for Health to the

HRSA Administrator, dated May 24,

1991.

This delegation is effective upon date

of signature. In addition, I hereby affirm

and ratify any actions taken by the

HRSA Administrator or any

subordinates which, in effect, involved

the exercise of the authorities delegated

herein prior to the effective date of the

delegation.

Dated: January 20, 1998.

Donna E. Shalala,

Secretary.

[FR Doc. 98–2040 Filed 1–27–98; 8:45 am]

BILLING CODE 4160–15–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee on Immunization

Practices: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Advisory Committee on

Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.–5:15 p.m.,

February 11, 1998; 8:30 a.m.–1:15 p.m.,

February 12, 1998.

Place: CDC, Auditorium B, Building 2,

1600 Clifton Road, NE, Atlanta, Georgia

30333.

Status: Open to the public, limited only by

the space available.

Purpose: The Committee is charged with

advising the Director, CDC, on the

appropriate uses of immunizing agents. In

addition, under 42 U.S.C. 1396s, the

Committee is mandated to establish and

periodically review and, as appropriate,

revise the list of vaccines for administration

to vaccine-eligible children through the

Vaccines for Children (VFC) program, along

with schedules regarding the appropriate

periodicity, dosage, and contraindications

applicable to the vaccines.

Matters To Be Discussed: Agenda items

will include updates from the National

Center for Infectious Diseases; the National

Immunization Program; the Vaccine Injury

Compensation Program; the National Vaccine

Program; update on influenza A(H5N1):

epidemiologic and virologic surveillance and

present status of vaccine development;

update on influenza surveillance—U.S. and

worldwide; influenza vaccination and

Guillain Barre syndrome: update and

proposed changes to ACIP recommendations;

proposed changes to the 1998–1999 ACIP

recommendations for prevention and control

of influenza; immunization of bone marrow

transplant recipients recommendations on

the use of Rotashield (rotavirus vaccine) as

part of the routine childhood immunization

schedule; report of work group on

computerization of ACIP recommendations;

ACIP combination vaccines recommendation;

comprehensive resolutions for the Vaccines

for Children (VFC) Program; vaccine

identification standards initiative; and

alopecia associated with hepatitis B

vaccination. Other matters of relevance

among the committee’s objectives may be

discussed.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Gloria A. Kovach, Committee Management

Specialist, CDC, 1600 Clifton Road, NE, M/

S D–50, Atlanta, Georgia 30333, telephone

404/639–7250.

Dated: January 21, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 98–1998 Filed 1–27–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing a

tentative schedule of forthcoming

meetings of its public advisory

committees for 1998. At the request of

the Commissioner of Food and Drugs

(the Commissioner), the Institute of

Medicine (the IOM) conducted a study

of the use of FDA’s advisory

committees. The IOM recommended

that the agency publish an annual

tentative schedule of its meetings in the

Federal Register. In response to that

recommendation, FDA is publishing its

annual tentative schedule of meetings

for 1998.

FOR FURTHER INFORMATION CONTACT:

Donna M. Combs, Committee

Management Office (HFA–306), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–827–

4820.

SUPPLEMENTARY INFORMATION: The IOM,

at the request of the Commissioner,

undertook a study of the use of FDA’s

advisory committees. In its final report,

the IOM recommended that FDA adopt

a policy of publishing an advance yearly

schedule of its upcoming public

advisory committee meetings in the

Federal Register. FDA has implemented

this recommendation. A tentative

schedule of forthcoming meetings will

be published annually in the Federal

Register. The annual publication of

tentatively scheduled advisory

committee meetings will provide both

advisory committee members and the

public with the opportunity, in advance,

to schedule attendance at FDA’s

upcoming advisory committee meetings.

The schedule is tentative and

amendments to this notice will not be

published in the Federal Register. FDA

will publish a Federal Register notice at

least 15 days in advance of each

upcoming advisory committee meeting,

announcing the meeting (21 CFR 14.20).

The following list announces FDA’s

tentatively scheduled advisory

committee meetings for 1998:

Committee Name Dates of Meetings InformationLine Code

OFFICE OF THE COMMISSIONER

Science Board to the Food and Drug Administration May 19 ......................................................................... 12603

September 15

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

Allergenic Products Advisory Committee March 23–24 ................................................................ 12388

September 14–15

Biological Response Modifiers Advisory Committee March 23–24 ................................................................ 12389